

New anti-migration intestinal stent

Patent Application Publication Dec. 11, 2014 Sheet 1 of 5 US 2014/0364959 A1




Fig. 1




Fig. 2

Partnership type

AP-HP is looking for an industrial partner for the development of the device and offers to grant license on the patent.

Background

In the US, nearly 1,5 million patients suffer from Crohn's disease. The most common complication is digestive stenosis (50% of patients).

If the stenosis measures less than 5 centimeters, an endoscopic dilatation is possible. However, it is associated with relapse rates of 30 to 50 % at 1-3 years. In this case, the patient undergoes another endoscopic dilatation or sometimes a bowel resection. The use of covered expandable metallic prostheses (used for malignant obstructions) could enhance the long-term efficacy of endoscopic dilatation. However, this solution is currently not possible, due to a high rate of uncontrolled migration (30 to 80% of cases).

Description of the technology

Our solution is a new stent with an original anti-migration design. It allows to treat patients with short benign stenosis (Crohn's diseases, post-operative colonic stenosis...) with a zero rate of migration (validated with metallic stent). A biodegradable version of this stent would allow a significant reduction in the risk associated with device removal (to be validated). The progressive and spontaneous disintegration of the biodegradable stent takes a few weeks and avoids the need for a second extraction colonoscopy and its complications.

Keywords

Digestive diseases - Stenosis - Cancer - Crohn's disease - Stricture - Stent - Anti-migration system

Intellectual property

Patent (EP2793747 - US2014364959)

Stage of development

Prototype - Clinical data available

Contacts:

Julien Matricon, PhD

33 (0) 1 44 84 17 18

Benoit Labarthe, PharmD, PhD

33 (0) 1 44 84 17 74

drc-licensing-ottpi@aphp.fr

Fax : 33 (0) 1 44 84 17 00